Given the critical roles of MMPs and TIMPs in cancer biology, we hypothesized that MMP-9, MMP-14, TIMP-1, and MMP-2 could serve as prognostic biomarkers for regorafenib efficacy in mCRC patients. Here, TIMP1 is linked to cancer.